Johnson & Johnson $JNJ Shares Purchased by Sound View Wealth Advisors Group LLC

Sound View Wealth Advisors Group LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 70,743 shares of the company’s stock after acquiring an additional 624 shares during the quarter. Sound View Wealth Advisors Group LLC’s holdings in Johnson & Johnson were worth $10,806,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of JNJ. Campbell & CO Investment Adviser LLC grew its holdings in shares of Johnson & Johnson by 1,165.7% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 27,466 shares of the company’s stock worth $4,195,000 after purchasing an additional 25,296 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in Johnson & Johnson by 45.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 173,936 shares of the company’s stock valued at $26,569,000 after buying an additional 54,683 shares during the last quarter. Delta Financial Advisors LLC boosted its stake in Johnson & Johnson by 0.5% during the second quarter. Delta Financial Advisors LLC now owns 25,853 shares of the company’s stock worth $3,949,000 after buying an additional 141 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Johnson & Johnson by 6.9% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,822,070 shares of the company’s stock valued at $736,658,000 after acquiring an additional 310,156 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its stake in shares of Johnson & Johnson by 4.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 18,965 shares of the company’s stock valued at $2,897,000 after acquiring an additional 834 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $186.50 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market cap of $449.34 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The stock’s 50-day moving average is $184.25 and its two-hundred day moving average is $168.70. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Analysts Set New Price Targets

A number of research firms recently weighed in on JNJ. Argus set a $210.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. HSBC boosted their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Barclays raised their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Finally, Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $199.05.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.